schliessen

Filtern

 

Bibliotheken

Diminishing the side effect of mitomycin C by using pH-sensitive liposomes: in vitro characterization and in vivo pharmacokinetics.

IntroductionMitomycin C is an anticancer antibiotic agent that has the potential for broad-spectrum use against several cancers, including mammary cancers. Because its half-life is 17 min after a 30 mg intravenous bolus administration, the suitability of mitomycin C for wide use in the clinical sett... Full description

Journal Title: Drug design development and therapy, 2018, Vol.12, pp.159-169
Main Author: Fang, Yi-Ping
Other Authors: Hu, Pei-Yu , Huang, Yaw-Bin
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 1177-8881 ; DOI: 10.2147/DDDT.S150201
Link: http://search.proquest.com/docview/1993993485/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest1993993485
title: Diminishing the side effect of mitomycin C by using pH-sensitive liposomes: in vitro characterization and in vivo pharmacokinetics.
format: Article
creator:
  • Fang, Yi-Ping
  • Hu, Pei-Yu
  • Huang, Yaw-Bin
subjects:
  • Animals–Administration & Dosage
  • Antibiotics, Antineoplastic–Adverse Effects
  • Cell Survival–Pharmacokinetics
  • Drug Delivery Systems–Drug Effects
  • Drug Stability–Metabolism
  • Folic Acid–Administration & Dosage
  • Half-Life–Adverse Effects
  • Humans–Pharmacokinetics
  • Hydrogen-Ion Concentration–Pharmacokinetics
  • Liposomes–Pharmacokinetics
  • Mcf-7 Cells–Pharmacokinetics
  • Male–Pharmacokinetics
  • Mitomycin–Pharmacokinetics
  • Particle Size–Pharmacokinetics
  • Rats–Pharmacokinetics
  • Rats, Sprague-Dawley–Pharmacokinetics
  • Antibiotics, Antineoplastic
  • Liposomes
  • Mitomycin
  • Folic Acid
  • Liposomes
  • Mitomycin C
  • Ph-Triggered Release
  • Pharmacokinetics
  • Side Effect
ispartof: Drug design, development and therapy, 2018, Vol.12, pp.159-169
description: IntroductionMitomycin C is an anticancer antibiotic agent that has the potential for broad-spectrum use against several cancers, including mammary cancers. Because its half-life is 17 min after a 30 mg intravenous bolus administration, the suitability of mitomycin C for wide use in the clinical setting...
language: eng
source:
identifier: E-ISSN: 1177-8881 ; DOI: 10.2147/DDDT.S150201
fulltext: fulltext
issn:
  • 11778881
  • 1177-8881
url: Link


@attributes
ID273325489
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid1993993485
sourceidproquest
recordidTN_proquest1993993485
sourcesystemPC
pqid1993993485
galeid576062041
display
typearticle
titleDiminishing the side effect of mitomycin C by using pH-sensitive liposomes: in vitro characterization and in vivo pharmacokinetics.
creatorFang, Yi-Ping ; Hu, Pei-Yu ; Huang, Yaw-Bin
contributorFang, Yi-Ping (correspondence author) ; Fang, Yi-Ping (record owner)
ispartofDrug design, development and therapy, 2018, Vol.12, pp.159-169
identifierE-ISSN: 1177-8881 ; DOI: 10.2147/DDDT.S150201
subjectAnimals–Administration & Dosage ; Antibiotics, Antineoplastic–Adverse Effects ; Cell Survival–Pharmacokinetics ; Drug Delivery Systems–Drug Effects ; Drug Stability–Metabolism ; Folic Acid–Administration & Dosage ; Half-Life–Adverse Effects ; Humans–Pharmacokinetics ; Hydrogen-Ion Concentration–Pharmacokinetics ; Liposomes–Pharmacokinetics ; Mcf-7 Cells–Pharmacokinetics ; Male–Pharmacokinetics ; Mitomycin–Pharmacokinetics ; Particle Size–Pharmacokinetics ; Rats–Pharmacokinetics ; Rats, Sprague-Dawley–Pharmacokinetics ; Antibiotics, Antineoplastic ; Liposomes ; Mitomycin ; Folic Acid ; Liposomes ; Mitomycin C ; Ph-Triggered Release ; Pharmacokinetics ; Side Effect
descriptionIntroductionMitomycin C is an anticancer antibiotic agent that has the potential for broad-spectrum use against several cancers, including mammary cancers. Because its half-life is 17 min after a 30 mg intravenous bolus administration, the suitability of mitomycin C for wide use in the clinical setting...
languageeng
source
version7
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/1993993485/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Fang, Yi-Ping
1Hu, Pei-Yu
2Huang, Yaw-Bin
titleDiminishing the side effect of mitomycin C by using pH-sensitive liposomes: in vitro characterization and in vivo pharmacokinetics.
descriptionIntroductionMitomycin C is an anticancer antibiotic agent that has the potential for broad-spectrum use against several cancers, including mammary cancers. Because its half-life is 17 min after a 30 mg intravenous bolus administration, the suitability of mitomycin C for wide use in the clinical setting...
subject
0Animals–Administration & Dosage
1Antibiotics, Antineoplastic–Adverse Effects
2Cell Survival–Pharmacokinetics
3Drug Delivery Systems–Drug Effects
4Drug Stability–Metabolism
5Folic Acid–Administration & Dosage
6Half-Life–Adverse Effects
7Humans–Pharmacokinetics
8Hydrogen-Ion Concentration–Pharmacokinetics...
9liposomes
10mitomycin C
11pH-triggered release
12pharmacokinetics
13side effect
general
0English
110.2147/DDDT.S150201
2MEDLINE (ProQuest)
3ProQuest Biological Science Collection
4ProQuest Natural Science Collection
5ProQuest SciTech Collection
6Biological Science Database
7Natural Science Collection
8SciTech Premium Collection
9Health Research Premium Collection
10Health Research Premium Collection (Alumni edition)
11Biological Science Index (ProQuest)
sourceidproquest
recordidproquest1993993485
issn
011778881
11177-8881
rsrctypearticle
creationdate2018
addtitleDrug design, development and therapy
searchscope
01007527
11007944
21009130
310000004
410000038
510000050
610000120
710000159
810000238
910000253
1010000260
1110000270
1210000271
1310000302
1410000350
15proquest
scope
01007527
11007944
21009130
310000004
410000038
510000050
610000120
710000159
810000238
910000253
1010000260
1110000270
1210000271
1310000302
1410000350
15proquest
lsr43
01007527false
11007944false
21009130false
310000004false
410000038false
510000050false
610000120false
710000159false
810000238false
910000253false
1010000260false
1110000270false
1210000271false
1310000302false
1410000350false
contributorFang, Yi-Ping
startdate20180101
enddate20180101
citationpf 159 pt 169 vol 12
lsr30VSR-Enriched:[pqid, galeid]
sort
titleDiminishing the side effect of mitomycin C by using pH-sensitive liposomes: in vitro characterization and in vivo pharmacokinetics.
authorFang, Yi-Ping ; Hu, Pei-Yu ; Huang, Yaw-Bin
creationdate20180101
lso0120180101
facets
frbrgroupid6877287709250947977
frbrtype5
newrecords20181218
languageeng
creationdate2018
topic
0Animals–Administration & Dosage
1Antibiotics, Antineoplastic–Adverse Effects
2Cell Survival–Pharmacokinetics
3Drug Delivery Systems–Drug Effects
4Drug Stability–Metabolism
5Folic Acid–Administration & Dosage
6Half-Life–Adverse Effects
7Humans–Pharmacokinetics
8Hydrogen-Ion Concentration–Pharmacokinetics...
collection
0MEDLINE (ProQuest)
1ProQuest Biological Science Collection
2ProQuest Natural Science Collection
3ProQuest SciTech Collection
4Biological Science Database
5Natural Science Collection
6SciTech Premium Collection
7Health Research Premium Collection
8Health Research Premium Collection (Alumni edition)
9Biological Science Index (ProQuest)
prefilterarticles
rsrctypearticles
creatorcontrib
0Fang, Yi-Ping
1Hu, Pei-Yu
2Huang, Yaw-Bin
jtitleDrug design, development and therapy
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Fang
1Hu
2Huang
aufirst
0Yi-Ping
1Pei-Yu
2Yaw-Bin
au
0Fang, Yi-Ping
1Hu, Pei-Yu
2Huang, Yaw-Bin
addauFang, Yi-Ping
atitleDiminishing the side effect of mitomycin C by using pH-sensitive liposomes: in vitro characterization and in vivo pharmacokinetics.
jtitleDrug design, development and therapy
risdate20180101
volume12
spage159
epage169
pages159-169
eissn1177-8881
formatjournal
genrearticle
ristypeJOUR
abstractIntroductionMitomycin C is an anticancer antibiotic agent that has the potential for broad-spectrum use against several cancers, including mammary cancers. Because its half-life is 17 min after a 30 mg intravenous bolus administration, the suitability of mitomycin C for wide use in the clinical setting...
doi10.2147/DDDT.S150201
urlhttp://search.proquest.com/docview/1993993485/
date2018-01-01